|
|
Volumn 29, Issue 3, 2011, Pages 177-178
|
|
Biosimilars encircle Rituxan, US debates innovator exclusivity.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRHEUMATIC AGENT;
MONOCLONAL ANTIBODY;
RITUXIMAB;
DEVICE APPROVAL;
DRUG APPROVAL;
DRUG INDUSTRY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LEGAL ASPECT;
NOTE;
PHARMACOKINETICS;
RHEUMATIC DISEASE;
UNITED STATES;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
ANTIRHEUMATIC AGENTS;
DEVICE APPROVAL;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMANS;
RHEUMATIC DISEASES;
THERAPEUTIC EQUIVALENCY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 79960095533
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0311-177 Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|
